ReviewAdvances in experimental medicine and biology2026
Clinical Proteomics Applied to Food Allergy.
Review in Advances in experimental medicine and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Food allergy (FA) is an immune-related condition, mainly characterized by hypersensitivity to food allergens in children and adults. Clinical proteomics is among the first medical disciplines supported by novel technologies, on the basis of which it becomes possible to understand FA from a therapeutic point of view. Within this chapter, three subdisciplines of proteomics will be covered: discovery clinical proteomics, targeted clinical proteomics, and clinical proteomics-based systems biology. Discovery clinical proteomics refers to the analysis of protein expression aiming at biomarker identification and knowledge about disease mechanisms which bring out completely new proteins connected to FAs. In targeted clinical proteomics, proteins that were identified in the exploratory studies are followed up so as to increase sensitivity for biomarkers detection in diagnostics. Proteomic-based systems biology is a means by which proteomics data can be integrated with other "omics" technologies for simulating immune response pathways governing biological systems and identifying therapeutic targets. Over the years, it has been possible to study what causes diseases, find new markers, and customize drug prescriptions according to protein results obtained from patients. Clinical proteomics has provided insight on immune responses, allergen diversity, and treatment possibilities in relation to FAs. It provides a detailed mapping of protein alterations as a result of allergens that are responsible for essential interactions with the immune system. In turn, clinical proteomics helps individualized medicine through identifying specific proteins signatures in patients enabling customized treatment approaches that will enhance its efficacy while mitigating any ill-effect. In this way, basic research is supposed to be united with clinical practice to offer novel opportunities for diagnosing, monitoring, and managing food allergic conditions that impact positively on outcomes leading to better life quality for patients.
Indexed as
Identifiers
42071156What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.